Creatine is best known as a sports supplement, but new research suggests it may also affect how some immune cells support the body’s response to cancer.
A study from researchers at the University of California, Los Angeles, found that creatine helped dendritic cells, a type of immune cell that helps start anti-cancer immune responses, work more effectively in laboratory tests and mouse models. The findings were published in iScience.
The research is at an early stage. It does not show that people with cancer should take creatine, and it does not prove that creatine improves cancer outcomes in patients. But it adds to growing interest in how metabolism, the way cells use energy, shapes the immune response to tumours.
Why dendritic cells matter in cancer
The immune system can recognise and attack cancer cells, but tumours often find ways to avoid or weaken that response.
Much of modern cancer immunotherapy focuses on T cells. These are immune cells that can kill infected or abnormal cells, including cancer cells. Treatments such as immune checkpoint inhibitors aim to release the brakes on T cells so they can attack tumours more effectively.
However, T cells usually need guidance before they act. That is where dendritic cells come in.
Dendritic cells collect fragments of tumour material and present them to T cells. In simple terms, they help show T cells what to look for. If dendritic cells are weak, poorly activated or unable to survive inside tumours, the wider immune response may be less effective.
This matters because current immunotherapies do not work for everyone. The UCLA researchers note that only around 20% to 40% of patients respond to many approved cancer immunotherapies. Improving the cells that prepare and direct T cells could be one way to help more patients benefit, although that remains to be tested in clinical trials.
What the new study found
The study looked at creatine, a naturally occurring compound involved in cellular energy use. Creatine is made by the body and is also obtained from foods such as meat and fish. Creatine monohydrate is widely used as a dietary supplement, particularly by athletes.
The researchers studied dendritic cells in mouse models of cancer and in human immune cells grown in the laboratory.
They first examined dendritic cells that had entered tumours in mice. These cells showed higher activity of a gene that makes the creatine transporter. This transporter helps bring creatine into cells.
That finding suggested dendritic cells inside tumours may have a particular need for creatine.
To test this, the researchers engineered dendritic cells that lacked the creatine transporter. Without the ability to take up creatine properly, these cells survived less well, showed weaker activation and were less able to prepare T cells to respond to tumours.
When these creatine-impaired dendritic cells were grown with T cells in the laboratory, the T cells divided less and produced fewer immune signalling molecules linked to anti-cancer activity.
The team then tested the opposite approach. In mouse models of melanoma, daily creatine injections slowed tumour growth and increased both the number and activation of dendritic cells within tumours.
The researchers also studied human monocyte-derived dendritic cells, a type of dendritic cell commonly used in experimental dendritic cell cancer vaccines. Creatine treatment appeared to improve their activation and their ability to stimulate human T cells against a cancer-associated target.
In plain language, the main finding is that creatine appeared to help dendritic cells generate and maintain the energy needed to support anti-tumour immune activity, at least in mice and laboratory-grown human cells.
How creatine may support immune cell function
Cells need energy to survive, communicate and carry out specialised tasks. For immune cells inside tumours, this can be difficult.
Tumours can create a harsh local environment. Cancer cells often consume large amounts of nutrients, leaving immune cells competing for fuel. They may also produce signals that suppress immune activity.
The UCLA team found that creatine supplementation increased levels of ATP inside dendritic cells. ATP is the main molecule cells use to power many of their functions.
Creatine is involved in an energy-buffering system inside cells. It helps cells manage short-term energy demand by supporting the recycling of ATP. For dendritic cells, this may help maintain activation and inflammatory signalling pathways needed to alert and instruct T cells.
How strong is the evidence?
The evidence is interesting but preliminary.
The study included mouse models and human cells grown in laboratory conditions. These are useful for understanding biology, but they cannot fully predict what will happen in patients with cancer.
Mouse tumours do not capture the full complexity of human cancer. Laboratory-grown immune cells also behave differently from immune cells inside a person’s body, where they are influenced by disease stage, previous treatments, genetics, nutrition, the microbiome and many other factors.
The research did not test creatine supplementation in cancer patients. It did not establish an effective dose for humans, identify which cancers might be most relevant or show whether creatine improves survival, response rates or quality of life.
It also used daily creatine injections in mice. That is not the same as taking an oral creatine supplement, and results cannot be directly translated into over-the-counter use.
What the study does show is a potential biological role for creatine uptake in dendritic cell function. That is a useful finding for immunology and cancer research, but it should not be treated as clinical proof.
What this means for patients and the public
This study does not change current medical advice.
People receiving cancer treatment should not start creatine or any other supplement without speaking to their oncology team. Supplements can sometimes interact with medicines, affect kidney-related monitoring, complicate surgery planning or create other risks depending on a person’s health and treatment plan.
Creatine monohydrate has been widely used for decades and is generally considered safe for many healthy adults when taken at recommended doses. However, “generally safe” does not mean safe or useful for every person with cancer.
Cancer patients often have complex medical needs. Kidney function, hydration status, weight changes, drug combinations and treatment side effects all matter. Decisions about supplements should be individual and medically supervised.
For the general public, the key message is not that creatine prevents or treats cancer. It is that researchers are learning more about how immune cell metabolism may affect the success of anti-cancer immune responses and exploring how creatine could help.
How this could fit with future treatments
Current cancer immunotherapies include immune checkpoint inhibitors, CAR-T cell therapies, cancer vaccines and other immune-based approaches. Many of these rely, directly or indirectly, on effective T cell responses.
Dendritic cell vaccines are another area of research and clinical use in selected settings. These involve preparing dendritic cells so they can present tumour-related targets to the immune system. The new study suggests that adding creatine during the manufacturing of dendritic cell vaccines might improve their quality or activity, but this remains experimental.
If future studies support the findings, creatine could potentially be tested in two broad ways.
One would be as a supportive supplement alongside immunotherapy, under clinical supervision, to see whether it improves immune responses or treatment outcomes.
The other would be as a laboratory tool used while preparing dendritic cell-based therapies before they are given to patients.
Both approaches would require carefully designed clinical trials to assess safety, dosing, timing and effectiveness.
The caveats
Several important questions remain.
Researchers still need to know whether creatine has the same immune effects in people with cancer as it does in mice and laboratory cell systems.
It is also unclear which patients, cancer types or immunotherapy regimens, if any, might benefit. Some tumours are more responsive to immune treatment than others, and the tumour environment can vary widely.
The best dose and form of creatine for immune effects are also unknown. The study does not show that standard sports supplement doses would reproduce the effects seen in experimental systems.
Researchers also need to assess whether creatine could have unwanted effects in some cancer contexts. Because cancer biology is complex, an intervention that helps immune cells in one setting may not have the same effect in another.
The UCLA team has said future work may include clinical trials testing whether creatine supplementation improves outcomes in patients receiving immunotherapy.
Potential new treatment
This research adds to evidence that immune cells need the right metabolic support to function well against cancer. It suggests creatine may help dendritic cells activate and support T cells in experimental models.
That is a meaningful scientific finding, but it is not yet a treatment finding.
For now, creatine should not be viewed as a cancer therapy or as a proven way to improve immunotherapy. Its potential role in cancer care remains a research question.
The wider lesson is that cancer immunotherapy is not only about activating killer T cells. It also depends on the cells that guide them, the nutrients available to them and the conditions inside tumours.
Understanding those factors may help researchers design better immune-based treatments in the years ahead and offers hope to cancer patients.
The post Creatine May Boost Immune System’s Respond to Cancer, Study Suggests first appeared on PP Health Malaysia.
